media – Page 571 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Biogen buys Pfizer’s unwanted neuro med for $75M as sell-off starts

As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
- Source: FierceBiotech
- 772
- March 13, 2018
Company Insight Pfizer pharmaceutical schizophrenia
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases

Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing.
- Source: silversteinfoundation.orgl
- 667
- March 13, 2018
financing gene Market Views Parkinson’s disease
The Menarini Group Announced Marketing Authorization Application for Delafloxacin

The Menarini Group announced today that on March 6th 2017 it submitted a Marketing Authorization Application for delafloxacin at the European Medicines Agency (EMA) under the trade name Quofenix. The proposed indication for delafloxacin in Europe is the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and the conclusion of the European regulatory process is expected in IIQ 2019.
- Source: finance.yahoo
- 489
- March 13, 2018
ABSSSI delafloxacin New Approvals
AliveCor smartphone add-on, algorithm discern high potassium levels in ECG data

An AliveCor algorithm has identified people with high potassium levels from electrocardiogram (ECG) data. Limited prospective clinical testing suggests pairing the algorithm with AliveCor’s smartphone and Apple Watch-based ECGs could enable the remote, noninvasive monitoring of potassium levels.
- Source: FierceBiotech
- 750
- March 13, 2018
ECG Researches wearables
HIV linked to higher risks for obesity, cardiovascular disease

HIV infection is associated with a greater risk for abdominal obesity and, perhaps indirectly, a greater risk for elevated LDL cholesterol and hypertriglyceridemia, according to recent findings.
- Source: healio
- 545
- March 13, 2018
cardiovascular disease HIV obesity Researches
Canon Medical launches new version of Aplio i900 cardiovascular ultrasound system

Canon Medical launches new version of Aplio i900 cardiovascular ultrasound system - Medical Devices Business Review
- Source: diagnosticimaging.medicaldevices-business-review.
- 597
- March 13, 2018
Canon cardiovascular ultrasound system medical device
Can An mHealth Kit Improve Outcomes in Workers Comp Treatment?

Cedars-Sinai will be testing a digital pain-reduction kit, which includes VR glasses and mHealth wearables, to see if mobile health technology can replace opioids for people recovering from workplace injuries.
- Source: mHealth Intelligence
- 808
- March 12, 2018
digital health mHealth Researches
Science 37 and Novartis Sign Strategic Alliance to Advance Decentralized Clinical Trials

Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis that will support the development of its new decentralized clinical trial (DCT) offerings. This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.
- Source: Science 37
- 577
- March 12, 2018
Company Insight digital health Novartis
Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

Pfizer Inc. announced a positive outcome from today’s U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer’s supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
- Source: finance.yahoo
- 709
- March 12, 2018
FDA Pfizer UC XELJANZ
Merck and Eisai Ink $5.76B Cancer Deal

Merck & Company and Tokyo-based Eisai Inc. have signed a strategic collaboration deal to develop and commercialize Lenvima (lenvatinib mesylate) with Merck’s anti-PD-1 drug Keytruda (pembrolizumab).
- Source: Biospace
- 522
- March 12, 2018
keytruda LENVIMA Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.